Evidence map›Paper›PMID 18541714›Full record

ArticleThe Journal of experimental medicine2008

An MHC class Ib-restricted CD8 T cell response confers antiviral immunity.

Phillip A Swanson, Christopher D Pack, Annette Hadley, Chyung-Ru Wang, Iwona Stroynowski, Peter E Jensen, Aron E Lukacher

Open access · bronzeAbstract read
In one paragraph

Article in The Journal of experimental medicine, 2008. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers.

0numbers the graph read from it
0cells of the map it votes in
24citing papers in PubMed
1.5field-weighted citation impact, top 18% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

24 citing papers in PubMed, 35 citations in OpenAlex.

  1. MHC class Ib-restricted CD8Proceedings of the National Academy of Sciences of the United States of America · 2023
    Article
  2. Article
  3. Article
  4. Qa-1-Restricted CD8Cell reports · 2019
    Article
  5. Review
  6. Article
  7. Review
  8. Article
  9. Article
  10. Review
  11. Article
  12. Review
  13. Article
  14. Article
  15. Article
  16. Review
  17. Article
  18. Review
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 4 institutions in 1 country.

Phillip A SwansonDepartment of Pathology, Emory University School of Medicine, Atlanta, GA 30322, USA.
Christopher D Pack
Annette Hadley
Chyung-Ru Wang
Iwona Stroynowski
Peter E Jensen
Aron E Lukacher
Emory University · USThe University of Texas Southwestern Medical Center · USUniversity of Chicago · USUniversity of Utah · US

Funding

The role of MHC class Lb in T cell development and infectious diseaseR01AI040310 · NIAID · UNIVERSITY OF CHICAGO · PI WANG, CHYUNG-RU · 2001 to 2016
$5.0M
T CELL IMMUNITY TO POLYOMA VIRUS INDUCED TUMORSR01CA071971 · NCI · PENNSYLVANIA STATE UNIV HERSHEY MED CTR · PI LUKACHER, ARON ELIOT · 2001 to 2011
$3.0M
TRANSPLANTION ANTIGENS--EXPRESSION AND FUNCTIONR01AI019624 · NIAID · UT SOUTHWESTERN MEDICAL CENTER · PI STROYNOWSKI, IWONA T · 1985 to 2007
$2.7M
Regulation of Polyoma Virus-Specific CD8+ T CellsR01CA100644 · NCI · EMORY UNIVERSITY · PI LUKACHER, ARON · 2003 to 2007
$1.4M
IMMUNITY TO INSULINR01AI033614 · NIAID · EMORY UNIVERSITY · PI JENSEN, PETER E. · 1993 to 2000
$287k
NCI NIH HHS R01 CA071971NCI NIH HHS R01 CA100644NCI NIH HHS R01CA100644NCI NIH HHS R01CA71971NIAID NIH HHS R01 AI019624NIAID NIH HHS R01 AI033614NIAID NIH HHS R01 AI040310NIAID NIH HHS R01AI19624NIAID NIH HHS R01AI33614NIAID NIH HHS R01AI40310
6 · The paper itself

Abstract

Although immunity against intracellular pathogens is primarily provided by CD8 T lymphocytes that recognize pathogen-derived peptides presented by major histocompatibility complex (MHC) class Ia molecules, MHC class Ib-restricted CD8 T cells have been implicated in antiviral immunity. Using mouse polyoma virus (PyV), we found that MHC class Ia-deficient (K(b-/-)D(b-/-)) mice efficiently control this persistently infecting mouse pathogen. CD8 T cell depletion mitigates clearance of PyV in K(b-/-)D(b-/-) mice. We identified the ligand for PyV-specific CD8 T cells in K(b-/-)D(b-/-) mice as a nonamer peptide from the VP2 capsid protein presented by Q9, a member of the beta(2) microglobulin-associated Qa-2 family. Using Q9-VP2 tetramers, we monitored delayed but progressive expansion of these antigen-specific CD8alphabeta T cells in K(b-/-)D(b-/-) mice. Importantly, we demonstrate that Q9-VP2-specific CD8 T cells more effectively clear wild-type PyV than a VP2 epitope(null) mutant PyV. Finally, we show that wild-type mice also generate Q9-restricted VP2 epitope-specific CD8 T cells to PyV infection. To our knowledge, this is the first evidence for a defined MHC class Ib-restricted antiviral CD8 T cell response that contributes to host defense. This study motivates efforts to uncover MHC class Ib-restricted CD8 T cell responses in other viral infections, and given the limited polymorphism of MHC class Ib molecules, it raises the possibility of developing peptide-based viral vaccines having broad coverage across MHC haplotypes.

Indexed as

AnimalsCapsid ProteinsCD8 AntigensCD8-Positive T-LymphocytesFemaleHistocompatibility Antigens Class ILymphocyte DepletionMaleMiceMice, KnockoutPapillomavirus VaccinesPolymorphism, GeneticPolyomavirusPolyomavirus InfectionsCapsid ProteinsCD8 antigen, alpha chainCD8 AntigensCD8beta antigenHistocompatibility Antigens Class IPapillomavirus VaccinesQ surface antigensVP2 protein, Polyomavirus

Identifiers

PMID18541714
PMCPMC2442642
OpenAlexW2000423452

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-SA
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.